The market for complex biologics including monoclonal antibodies, bispecific antibodies and fusion molecules is growing at a rapid pace.

On the long and costly path to market, early development decisions that prepare a molecule for its clinical journey are among the most critical.

As the injectable drug market continues to expand - driven by the rise of biologics, biosimilars, and patient-centric therapies-pharmaceutical companies face increasing pressure to differentiate their products, reduce costs, and optimize delivery systems.

Establishing strong process characterization and validation early is critical to ensuring biologics are developed efficiently, in compliance, and ready for scale—but these steps are often underestimated and overlooked until late in development.